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Genetics play a major role in the development of venous thromboembolism (VTE). However, current 
thrombophilia testing identifies a known heritable defect in only a minority of VTE patients.1 A part of 
this missing heritability for VTE may be caused by rare variants.2  In the current study we combined  
genome-wide linkage analysis with whole-exome sequencing (WES) and identified a rare novel 
prothrombin (F2) gene mutation (c.1621C>T; p.Arg541Trp hereafter referred to as p.Arg173Trp 
according to chymotrypsin numbering) in a Dutch family with unexplained thrombosis.  
The proband, from Dutch Caucasian ancestry, presented at age 31 with a first deep vein thrombosis 
(DVT) during pregnancy. Shortly after, her father had DVT after hospitalization at age 58. The family 
was aware that they were prone for thrombosis, and offered a family tree of the older generations. 
The proband’s paternal uncle had had spontaneous PE at age 38 and age 42, a cousin had a 
spontaneous DVT at age 44 (data obtained from the subjects themselves, VTE diagnoses in 
generations I, II and III were obtained from family members). Routine thrombophilia testing in the 
proband was negative, excluding deficiencies of antithrombin, protein C, protein S, and factor V 
Leiden and prothrombin G20210A mutation. In the years after, both the proband and her father had 
a spontaneous DVT recurrence, and the proband’s younger sister presented with estrogen-related 
PE. We hypothesized that this family carried a private, high risk mutation. After informed consent 
was obtained we included a total of 19 family members for testing.  
First, genome-wide SNP genotyping was performed on 19 family members (5 affected and 14 
unaffected; Figure 1A) (Online Supplementary) and identified twelve chromosomes with equally high 
significant linkage peaks (LOD > 1). These chromosomes were: 3, 4, 7, 9, 11, 13, 14, 18, 19, 20, 22, 
and X. Next, WES was performed on 5 family members (4 affected: 26101, 26103, 26105, 26206; 1 
unaffected: 26312; Figure 1A) (Online Supplementary). In total, 138,672 variants were detected, of 
which, after rigorous filtering, 113 remained common among affected family members. When we 
combined these results with linkage data, e.g. filtering based on their distance (˜ 3 Mb) to the linkage 
peak, 30 variants remained. In the final step, in silico prediction was performed with MetaSVM and 
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MetaLR thereby identifying 1 potentially pathogenic novel prothrombin (F2) gene mutation 
(p.Arg173Trp) (Figure 1B) located on chromosome 11. Using Sanger sequence analysis we confirmed 
the heterozygous presence of a novel prothrombin (F2) gene mutation (Figure 1C). Next, with a 
custom made TaqMan qPCR assay (Applied Biosystems) we confirmed the presence of the 
prothrombin (F2) gene mutation p.Arg173Trp in 4 affected family members (26101, 26103, 26105, 
26206), whereas 1 unaffected family member (216209) also carried this mutation (Figure 1D). 
Furthermore, one family member who did not carry the mutation (216418) had a history of deep 
vein thrombosis.  
Functional testing was complicated due to the use of vitamin K antagonists in the carriers of the 
prothrombin mutation with available plasma. We therefore performed functional assays with 
recombinant prothrombin molecules (U-Protein Express BV Utrecht, the Netherlands). A 
hydroxyapatite column was used to obtain fully γ-carboxylated wild-type and mutant prothrombin. 
Prothrombin levels were measured a by one-stage clotting assay on an automated coagulation 
analyser (ACL 300 TOP) with reagents and protocols from the manufacturer (Instrumentation 
Laboratory, Breda, The Netherlands). At a final concentration of 90 μg/ml in prothrombin deficient 
plasma, the recombinant wild-type and mutant prothrombins had prothrombin activity of 82% and 
67%, respectively. Furthermore, thrombin generation was performed using calibrated automated 
thrombography and Thrombinoscope software according to the manufacturer’s instruction 
(Thrombinoscope BV, Maastricht, The Netherlands). Recombinant wild-type or p.Arg173Trp 
prothrombin was added to prothrombin deficient plasma (Siemens) at a final concentration of 90 
μg/ml in the absence or presence of 0.1 U/ml unfractionated heparin (LEO Pharma BV) and in vitro 
thrombin generation was assessed. Figure 1E depicts representative thrombin generation curves. In 
the absence of unfractionated heparin, plasma containing p.Arg173Trp prothrombin had a 
substantially higher endogenous thrombin potential as compared to plasma to which wild-type 
prothrombin was added (2400 ± 113 vs 797 ± 42 nM IIa*min, p<0.0001, n=3). Addition of 
unfractionated heparin reduced thrombin generation in plasma containing the p.Arg173Trp 
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prothrombin by only 7.3 ± 3.9% compared to a 31.4 ± 9.3% reduction in thrombin generation in 
plasma containing wild-type prothrombin (p=0.01, n=3). 
Finally, we performed molecular dynamics in order to simulate the effect of the p.Arg173Trp 
mutation (Online Supplementary). The prothrombin (F2) gene mutation is located in the 170s loop, 
near the non-primed side of the active site (Figure 2A). The results of molecular dynamics are 
consistent with a conformational alteration in the non-prime side of the active site due to the 
repositioning of the Trp173 side chain to minimize its solvent accessibility by packing up against 
Trp215 (Figure 2B).  
Venous thrombosis is a disorder in which genetic predisposition plays an important role. However, in 
a large portion of patients with VTE no genetic defect can be detected. Several aspects contribute to 
the missing heritability for VTE, including rare variants. To identify such variants we combined linkage 
analysis with WES and found a novel prothrombin (F2) gene mutation p.Arg173Trp. 
This mutation is assumed to be rare as it was absent in 2 control groups, e.g. in 24 probands of 
families with unexplained thrombosis and 100 healthy volunteers without VTE (selection from GoNL; 
http://www.nlgenome.nl/) (data not shown). Furthermore, this mutation was not present in dbSNP 
(https://www.ncbi.nlm.nih.gov/snp) or HGMD (http://www.hgmd.cf.ac.uk/ac/index.php).    
Prothrombin deficiency has long been considered to only be associated with bleeding tendency until 
Miyawaki et al. reported in 2012 on a family with dysprothrombinemia and venous thrombosis.3 This 
dysprothrombinemia was caused by a substitution of arginine to leucine at position 221a in F2 gene 
(prothrombin Yukuhashi).3 In the following years, 2 additional mutations at position 221a were 
reported, e.g. prothrombin Belgrade4 and prothrombin Padua 2.5 Apart from prothrombin Belgrade, 
these mutations were all associated with a strong risk of VTE at young age.
3, 5
 The association with 
VTE was explained by antithrombin resistance caused by mutations at position 221a.
3-5   
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All carriers of the prothrombin (F2) gene mutation p.Arg173Trp, with the exception of 216209 have 
had venous thrombosis. One family member who did not carry the mutation (216418) also had a 
history of deep vein thrombosis. We cannot exclude that additional unknown thrombophilic factors 
are present in the family. We have also observed in studies of protein C, S and antithrombin 
deficiency that non-affected family members have a higher incidence of VTE than the normal 
population.6 However, venous thromboembolism is a common disorder and this one case in a family 
member without the mutation might also have been due to chance. 
Our functional studies showed a clear heparin resistance that is suggestive for antithrombin 
resistance. In line with this, Tamura et al. performed an in vitro exploratory study using prothrombin 
mutants and showed that a recombinant p.Arg173Trp mutation exhibited a mild antithrombin 
resistance.7  
The side chain of p.Arg173 is not fully modeled in the structure of the antithrombin-thrombin 
Michaelis complex, suggesting that it is not making a single distinct contact with antithrombin. It is in 
a position where it could exert favorable long-range electrostatic influence on docking, since it is in 
the vicinity of glutamates 232, 377 and 378 on antithrombin. However, such an influence would be 
overwhelmed by the magnitude of the effect of heparin on the association rate. The heparin 
resistance of the p.Arg173Trp thrombin variant therefore suggests something more profound than 
the loss of a favorable interaction or electrostatic influence. What is more likely is a structural 
rearrangement of the active site caused by the introduction of a large hydrophobic residue to a 
solvent-exposed loop (Figure 2A). The 170s loop has been implicated in the zymogen to protease 
conformational change and allosteric activation. The molecular dynamics results suggest a distinct 
conformational change in the non-prime side of the active site due to the Trp173 burying itself as 
much as possible thereby interfering with antithrombin inhibition (Figure 2B). However, more 
evidence is still needed to conclude that the prothrombin mutation p.Arg173Trp leads to 
antithrombin resistance.  
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Finally, at a final concentration of 90 μg/ml in deficient plasma, the recombinant wild-type and 
mutant showed borderline low prothrombin activity levels, which is in contrast with the increased 
thrombin potential observed with the thrombin generation assay. Such a discrepancy has also been 
observed for 4 antithrombin-resistant mutations in position 221a,7 . This discrepancy could be 
explained by the fact that clotting assays measure only the clotting time corresponding to the 
initiation phase of the coagulation process, whereas thrombin generation assays also provide 
information about the amplification and propagation phases of the hemostatic system.  
In conclusion, in this study we identified a rare novel prothrombin (F2) gene mutation p.Arg173Trp 
that causes heparin resistance which is suggestive for antithrombin resistance. Evidently further 
investigations are needed to fully disentangle the mechanism responsible for the potential 
association between the prothrombin (F2) gene mutation p.Arg173Trp and venous thrombosis.  
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Figure 1. Identification and functional characterization of novel prothrombin (F2) gene mutation in a 
Dutch family with unexplained thrombosis. A. The pedigree. The arrow indicates the proband. Roman 
numbers denote the generation in the pedigree; study number of included family members is 
depicted below each symbol; square symbols, male sex; round symbols, female sex; solid symbols 
represent VTE-affected family members, open symbols represent unaffected family members. B. 
WES combined with linkage analysis. The diagram depicts effects of filtering WES data based on 
specific aspects including among other things such as type of mutation and location to linkage peak. 
C. Direct sequencing results of exon 12 of F2 gene. The prothrombin (F2) gene mutation (c.1621C>T; 
p.Arg173Trp) is highlighted. D. This figure shows the genotyping results of a custom made Taqman 
qPCR assay for 19 included family members. The green lines represent the carriers of the 
prothrombin (F2) gene mutation (26101, 26103, 26105, 26206, and 26209), whereas red lines 
represent the non-carriers of the mutation (26102, 26104, 26207, 26208, 26210, 26211, 26312, 
26313, 26314, 26315, 26316, 26317, 26418, and 26419). E. Thrombin generation in prothrombin 
depleted plasma supplemented with wild-type (WT) and mutant protein in the presence or absence 
of 0.1 U/ml unfractionated heparin.  
 
Figure 2. Structural characterization of novel prothrombin (F2) gene mutation. A. A ribbon diagram of 
the heavy chain of thrombin in the standard orientation showing the position of the mutation (side 
chain of Arg173 as sticks) and the Na+ (purple ball) binding site (colored from N-to-C terminus, blue 
to red). B. Surface representation of the resulting structures after molecular dynamics simulation of 
wild-type (left) and the p.Arg173Trp mutant variant (right) thrombin coloured according to 
electrostatics. Oval indicates the non-primed side of the active site cleft, and arrow indicates the 
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Genomic DNA  
Genomic DNA was obtained from citrated and EDTA samples using the Qiacube system. 
Linkage analysis 
Genome-wide SNP genotyping was performed on 19 family members (5 affected and 14 unaffected; 
Figure 1A) using Illumina Infinium Core Exome-24v1.1 bead chip. The bead chip included 551,839 SNP 
markers distributed evenly across the genome. The mean and median intervals between markers 
were 5.26 kb and 1.82 kb, respectively. 
For linkage analysis, we first excluded SNPs with genotype call rate less than 95%, MAF less than 
0.001 and HWE test p-value less than 0.0001. Next, frequency and genotyping pruning was 
performed. From the subset, SNPs were checked for strong LD, since high LD within dense SNP 
regions can result in false positive results. We applied prune SNPs within strong LD using –indep 50 5 
10 option in PLINK v1.07. Strong LD pruning can be defined as removing SNPs within a 50 SNP 
window, with 5 SNPs to shift the window at each step that had r^2>0.9 (corresponding to a variance 
inflation factor, VIF, greater than 10) with all other SNPs in the window. We then checked the SNPs 
with Mendelian inheritance error using Pedstats program1 and masked the genotypes for the SNPs 
with error using Pedwipe program. For pruned and masked SNP data, non-parametric linkage 
analyses will be performed using the Merlin 1.1.2.2 We performed non-parametric analyses to get 
LOD scores and statistics. A LOD score of more than 0 would be suggestive for evidence of linkage.  
Whole exome sequencing (WES) 
The SureSelect Human All Exon V5 was used for WES on 5 family members (4 affected: 26101, 26103, 
26105, 26206; 1 unaffected: 26312; Figure 1A). 
Read mapping  
Paired-end sequences produced by HiSeq Instrument were first mapped to the human genome, with 
the reference sequence as UCSC assembly hg19 (original GRCh37 from NCBI, Feb. 2009), and without 
unordered sequences or alternate haplotypes. ‘BWA’ (version 0.7.12) was used as the mapping tool, 
which generates the mapping result file in BAM format using ‘BWA-MEM’. Then, programs within 
Picard-tools (ver.1.130) were used in order to remove PCR duplicates, reducing those reads to 
identically match to a position at start into a single one, using MarkDuplicates.jar, which requires 
reads to be sorted. The local realignment process were performed to consume BAM files and to 
locally realign reads such that the number of mismatching bases is minimized across all reads. Base 
quality score recalibration (BQSR) and local realignment around indels were performed using 
Genome Analysis Toolkit to locally realign reads such that the number of mismatching bases was 
minimized. 
Variant calling and annotation  
Based on the BAM file previously generated, variant genotyping for each sample was performed with 
Haplotype Caller of GATK (v3.4.0). In this stage SNPs and short indels candidates were detected at 
the nucleotide resolution. These variants were annotated by a program called SnpEff v4.1g and 
converted to vcf file format. They were filtered with dbSNP version 142, and SNPs from the 1000 
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genome project. Then, in-house program and SnpEff were applied to filter additional databases, 
including ESP6500, ClinVar, dbNSFP2.9. 
Family analysis 
To identify the genetic variants underlying rare diseases, variants in all family members were joint-
called with GATK (v3.4.0) and filtered with an in-house developed script. Firstly, exon-, exonic-
splicing, and splicing regions are selected to merge variant data. Synonymous single nucleotide 
variants (SNVs) within the remaining variants were then removed. Furthermore, dbSNP135 common 
(freq>=1%) and 1000 genome freq >0.01 variants were eliminated. Next, variants uncommon among 
affected family members were filtered out. In addition, only variants at chromosomes with linkage 
peaks were further filtered based on their distance (˜ 3 Mb) to the linkage peak. Remaining variants 
with variant ids were then filtered out. Finally, variants in genes known to be associated with 
coagulation were selected and further filtered based on the in silico prediction where only variants 
that scored deleterious with MetaSVM and MetaLR remained.3 
 
Molecular dynamics 
The starting model for the molecular dynamics simulation was thrombin from  1JOU (chains A and B), 
including surrounding water molecules and sodium ion, modified by mutation of Ala195 back to Ser 
and Arg173 to Trp. The simulation was conducted using the program YASARA within a hydrated box 
surrounding the thrombin molecule.4, 5 The YAMBER forcefield was used with simulated annealing at 
335K. The parent molecule (p.Ala195Ser) was run for 18 ps to obtain the minimized starting structure 
which did not result in significant changes. Arg173 was then mutated to Trp and the simulation was 
restarted. In order to bury the side chain of Trp173 it was selected and pulled toward the S4 pocket, 
followed by 26 ps of energy minimization with simulated annealing.  
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